NL-OMON21311Other不适用
Myeloid cell reprogramming in the context of radioiodine therapy in patients with non-medullary thyroid carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- Other
- 发起方
- Radboudumc
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •In general: Subjects should be at least 18 years old and mentally competent
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •-Mentally incompetent
研究者
相似试验
已完成
不适用
Myeloid cell reprogramming in the context of radioiodine therapy in patients with non-medullary thyroid carcinomathyroid carcinomaNL-OMON48852Radboud Universitair Medisch Centrum50
尚未招募
不适用
Investigation of the T cell metabolic reprogramming during immunotherapy in oncologic patientsC43Malignant melanoma of skinDRKS00023625niversitätsklinikum Freiburg50
已完成
不适用
Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis1001108210003216atherosclerosisNL-OMON38690niversitair Medisch Centrum Sint Radboud40
进行中（未招募）
1 期
START-NET: A randomized clinical trial to compare personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOCPatients with SSTR+, advanced, progressive NET Grade 1-3 of any origin for whom Peptide-receptor radionuclide therapy, PRRT, is considered the mostappropriate treatment option in relation to other approved or available investigational agents for the specific tumor subtype.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002218-15-SERegion Skåne300
尚未招募
3 期
GUM THICKNESS MODIFICATION TRIACTRI/2022/12/048131MINISTRY OF DEFENCE